# Shuhao Wen

> Shuhao Wen is a seed investor at XtalPi (Cambridge) backing Biotechnology and Medical. See 7 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [XtalPi](https://shizune.co/investors/profile/xtalpi)
- Location: Cambridge, United States
- Total investments: 7
- Last investment: Apr 2026
- Lead investor: 29%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/shuhao-wen-a1810356/

Shuhao Wen is a Founder at XtalPi.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 5 | 71% |
| Medical | 3 | 43% |
| Pharmaceutical | 3 | 43% |
| Artificial Intelligence | 2 | 29% |
| Genetics | 1 | 14% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 3 | 43% |
| Series A | 3 | 43% |
| Venture - Series Unknown | 1 | 14% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 3 | 43% |
| China | 2 | 29% |
| Switzerland | 1 | 14% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Xellar Biosystems | Xellar Biosystems is a wet artificial intelligence biotechnology company that provides analysis of drug testing and treatment. | $29M | Series A | Apr 02, 2026 |  |
| Signet Therapeutics | Signet Therapeutics is a cutting-edge firm that conducts research and development on cancer-targeted drugs using AI and organoid disease models. | $11.5M | Series A | Jan 14, 2026 |  |
| Xellar Biosystems | Xellar Biosystems is a wet artificial intelligence biotechnology company that provides analysis of drug testing and treatment. |  | Seed | Apr 28, 2025 |  |
| FuChe Biotech | FuChe Biotech is a biotechnology startup which Empower a clear future and innovative technology. |  | Seed | Feb 27, 2025 |  |
| META Pharmaceuticals | META Pharmaceuticals is a cutting-edge drug development company specializing in autoimmune diseases. |  | Venture - Series Unknown | Feb 17, 2025 |  |
| ReviR Therapeutics | ReviR Therapeutics is a genomics-based platform that develops novel medicines targeting human RNAs. | $30M | Series A | Jul 26, 2024 |  |
| Leman Biotech | Leman Biotech is a biotech company that is engaged in development of cancer immunotherapies. | $7M | Seed | Jun 18, 2024 |  |

7 of 7 investments shown.

## Co-investors
- [Yael Capital Management Limited](https://shizune.co/investors/profile/yael-capital-management-limited) — VC Fund, 4 deals together
- [Tiantu Capital](https://shizune.co/investors/profile/tiantu-capital) — VC Fund, 3 deals together
- [IMO Ventures](https://shizune.co/investors/profile/immersion-ventures) — VC Fund, 2 deals together
- [Blue Ocean Capital Group](https://shizune.co/investors/profile/blue-ocean-capital) — VC Fund, 1 deal together
- [Capital O](https://shizune.co/investors/profile/capital-o) — VC Fund, 1 deal together
- [CDH Investments](https://shizune.co/investors/profile/cdh-investments) — VC Fund, 1 deal together

## About XtalPi

VC Fund · Cambridge, United States

XtalPi is a pharmaceutical technology company that is reinventing the industry’s approach to drug research and development with its Intelligent Digital Drug Discovery and Development (ID4) platform. Through its tightly interwoven quantum mechanics, artificial intelligence, and high-performance cloud computing algorithms, the ID4 platform enablespharmaceutical companies to increase their efficiency, accuracy, and success rate at critical stages of drug R&D. By accelerating the pace of drug discovery and development, XtalPi aims to contribute to a healthier society worldwide.Founded in 2014 by a group of quantum physicists at MIT, XtalPi has since grown into an elite team of researchers with multi-disciplinary expertise in physics, chemistry, pharmaceutical R&D, and algorithm design. XtalPi has received much recognition for its cutting-edge technologies, its innovative solutions, and the breadth of potential applications of its offerings across the pharmaceutical value chain, which has allowed it to gain industry approval and establish strategic partnerships with several top international pharmaceutical companies.

5 contacts available at XtalPi.

| Name | Title | Profile |
| --- | --- | --- |
| William Glauser | Senior Vice President of Business Strategy | https://shizune.co/investors/profile/william-a-glauser |
| Jian Ma | Co-Founder and CEO | https://shizune.co/investors/profile/jian-ma |
| Lipeng Lai | Co-Founder | https://shizune.co/investors/profile/lipeng-lai |
| Sarah Trice | COO, Head of US Operations | https://shizune.co/investors/profile/sarah-trice-c8d2 |
| Shuhao Wen | Founder | https://shizune.co/investors/profile/shuhao-wen |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Shuhao Wen invest in?

Shuhao Wen invests primarily in Biotechnology, Medical and Pharmaceutical startups, most often at Seed and Series A stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Shuhao Wen last invest?

The most recent investment recorded for Shuhao Wen closed in Apr 2026. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co